SCYL3 Antikörper (C-Term)
Kurzübersicht für SCYL3 Antikörper (C-Term) (ABIN2356858)
Target
Alle SCYL3 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
- 
    
- 
                                            
Bindungsspezifität
 - AA 670-699, C-Term
 - 
                                            
Kreuzreaktivität
 - Maus
 - 
                                            
Kreuzreaktivität (Details)
 - Calculated cross reactivity: Mo
 - 
                                            
Produktmerkmale
 - Scyl3, CT (Scyl3, Pace1, Protein-associating with the carboxyl-terminal domain of ezrin, Ezrin-binding protein PACE-1, SCY1-like protein 3)
 - 
                                            
Aufreinigung
 - Purified by Protein A affinity chromatography.
 - 
                                            
Immunogen
 - Mouse Scyl3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 670-699 amino acids from the C-terminal region of Mouse Scyl3.
 - 
                                            
Isotyp
 - IgG
 
 - 
                                            
 - 
    
 - 
    
- 
                                            
Applikationshinweise
 - Optimal working conditions should be determined by the investigator.
 - 
                                            
Beschränkungen
 - Nur für Forschungszwecke einsetzbar
 
 - 
                                            
 - 
    
- 
                                            
Format
 - Liquid
 - 
                                            
Buffer
 - Supplied as a liquid in PBS, pH 7.2, 0.09 % sodium azide.
 - 
                                            
Konservierungsmittel
 - Sodium azide
 - 
                                            
Vorsichtsmaßnahmen
 - This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
 - 
                                            
Lagerung
 - -20 °C
 - 
                                            
Informationen zur Lagerung
 - -20°C
 
 - 
                                            
 - 
    
 -